Genprex, INC. 8-K Filing
Ticker: GNPX · Form: 8-K · Filed: Nov 4, 2025 · CIK: 1595248
Sentiment: neutral
Filing Stats: 1,045 words · 4 min read · ~3 pages · Grade level 15.4 · Accepted 2025-11-04 07:10:25
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
Filing Documents
- gnpx20251024_8k.htm (8-K) — 32KB
- 0001437749-25-032870.txt ( ) — 164KB
- gnpx-20251104.xsd (EX-101.SCH) — 3KB
- gnpx-20251104_def.xml (EX-101.DEF) — 12KB
- gnpx-20251104_lab.xml (EX-101.LAB) — 15KB
- gnpx-20251104_pre.xml (EX-101.PRE) — 12KB
- gnpx20251024_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On November 4, 2025, Genprex, Inc. ("Genprex" or the "Company") issued a press release in which it announced that the European Patent Office has communicated its intent to grant Genprex a patent for the use of Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer. The press release also noted that this patent, if granted, will expand on the previously granted patents for REQORSA in combination with PD-1 antibodies, which have been granted in the U.S., Japan, Mexico, Russia, Australia, Chile, China, and Singapore. REQORSA is initially being developed in combination with prominent, approved cancer drugs to treat lung cancer. In preclinical studies, REQORSA has been shown to be complementary with targeted drugs and immunotherapies. The Company believes REQORSA's unique attributes position it to provide potential treatments that improve on these current therapies for patients with lung cancer and possibly other cancers. Cautionary Language Concerning Forward-Looking Statements Because forward-looking statements are subject to risks and uncertainties, actual results may differ mater
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: November 4, 2025 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)